Tildrakizumab Shows Significant Efficacy After IL-17 Treatment Failure

A new study reveals that Tildrakizumab improves psoriasis outcomes significantly after patients fail anti-IL-17 therapies.

A
Aapla Nagpur Desk
18 Nov 2026, 7:33 PM IST · 2 min read
Source: Emjreviews
Tildrakizumab Shows Significant Efficacy After IL-17 Treatment Failure
KEY TAKEAWAYS
1

66.7% of patients achieved PASI90 after 52 weeks of Tildrakizumab treatment.

2

Mean PASI scores dropped from 12.2 to 1.1, indicating substantial improvement.

3

Dose escalation to 200 mg was common, with no patients remaining on the lower dose.

In a recent study, Tildrakizumab, an IL-23 inhibitor, demonstrated considerable effectiveness in treating moderate-to-severe plaque psoriasis in patients who had previously failed anti-IL-17 therapies. Over a 52-week period, data from 30 patients indicated significant clinical improvements, as measured by the Psoriasis Area and Severity Index (PASI).

The research focused on individuals who had not responded to a single IL-17 inhibitor before transitioning to Tildrakizumab. Clinical assessments revealed that mean PASI scores decreased dramatically from 12.2 at the start of the study to just 1.1 by week 52. Additionally, 88.9% of participants achieved at least a 75% improvement in their PASI scores, with 66.7% reaching PASI90 and 50% achieving complete clearance (PASI100).

Patient-reported outcomes also reflected significant enhancements, with improvements noted in the Dermatology Life Quality Index (DLQI) and the WHO-Five Well-Being Index (WHO-5). Treatment satisfaction remained notably high throughout the study, suggesting that Tildrakizumab not only alleviated clinical symptoms but also positively impacted patients' quality of life.

The study highlighted a frequent need for dose escalation, as all patients who started on 100 mg of Tildrakizumab were eventually increased to 200 mg during the follow-up period. This raises questions about the efficacy of the lower dose, as there was no comparator group maintained on 100 mg to evaluate the relative effectiveness of the higher dosage.

Overall, the findings suggest that switching to Tildrakizumab can provide sustained benefits for patients with moderate-to-severe plaque psoriasis following the failure of IL-17 inhibitors. The study underscores the importance of ongoing research to further understand optimal dosing strategies and long-term outcomes for this patient population.

💬What did you think of this story?What did you think?

Read Next

Tildrakizumab Efficacy After IL-17 Failure